BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG

Stock Information for Heartbeam Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Heartbeam Inc.

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application
HeartBeam Reports Third Quarter 2025 Results
HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time
HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere
HeartBeam's Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias
HeartBeam to Participate at Upcoming Industry and Investor Conferences, September 4-10, 2025
HeartBeam Reports Second Quarter 2025 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.